v3.25.4
Revenues (Tables)
12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table presents a summary of total revenues (in thousands):
Year Ended December 31,
202520242023
Xywav$1,656,986 $1,473,202 $1,272,977 
Xyrem146,034 233,816 569,730 
Epidiolex/Epidyolex1,059,197 972,423 845,468 
Sativex1
16,277 18,877 19,668 
Total Neuroscience2,878,494 2,698,318 2,707,843 
Rylaze/Enrylaze402,920 410,846 394,226 
Zepzelca307,309 320,318 289,533 
Defitelio/defibrotide 199,392 216,565 184,000 
Vyxeos146,709 162,595 147,495 
Modeyso48,043 — — 
Ziihera24,810 1,051 — 
Total Oncology1,129,183 1,111,375 1,015,254 
Other14,172 11,471 13,846 
Product sales, net4,021,849 3,821,164 3,736,943 
High-sodium oxybate AG royalty revenue211,725 217,575 75,918 
Other royalty and contract revenues34,012 30,211 21,343 
Total revenues$4,267,586 $4,068,950 $3,834,204 
____________________________
(1) Divestiture of Sativex was completed in October 2025.
The following table presents a summary of total revenues attributed to geographic sources (in thousands):
Year Ended December 31,
202520242023
United States$3,831,598 $3,660,109 $3,489,977 
Europe341,122 312,706 269,243 
All other94,866 96,135 74,984 
Total revenues$4,267,586 $4,068,950 $3,834,204 
Schedule of Percentage of Total Revenues from Customers
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:
Year Ended December 31,
202520242023
ESSDS42%42%48%
ASD11 %9 %7 %
McKesson10%12%11%